Peregrine Pharmaceuticals, Inc. has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a second, late-stage trial. The companies will now evaluate the combination of Peregrine’s phosphatidylserine (PS)-targeted immune-activator, bavituximab, and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), in a global Phase II study in previously treated squamous or non-squamous non-small cell lung cancer (NSCLC). Peregrine will conduct th...